Markets:

Overview

News

Currencies

International

Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

151.42 +10.62 (+7.54%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript ↗

August 10, 2026

AI-enabled drug discovery orders drive triple-digit growth as guidance rises.

Via The Motley Fool

Topics Earnings

Twist Bioscience Sees AI Drug Discovery Pipeline Expand ↗

August 03, 2026

Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth.

Via Benzinga

Topics Artificial Intelligence

Twist Bioscience Q3 Earnings Call Highlights ↗

August 03, 2026

Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year...

Via MarketBeat

Topics Earnings

Twist Bioscience TWST Q2 Fiscal 2026: Revenue Beat Offset by Wider EPS Miss ↗

May 04, 2026

Via Chartmill

TWIST BIOSCIENCE CORP (NASDAQ:TWST) Reports Mixed Q1 FY2026 Results with Revenue Beat and Wider Loss ↗

February 02, 2026

Via Chartmill

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

Cathie Wood Is Selling This High-Flying Stock. Is It a Buy? ↗

July 19, 2026

Wood's ETFs sell stocks that have had strong runs to pay for other positions.

Via The Motley Fool

Topics ETFs

The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own ↗

June 19, 2026

AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.

Via The Motley Fool

Topics Artificial Intelligence

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors. ↗

June 12, 2026

This synthetic DNA specialist, leveraging silicon chip technology, reported a notable insider sale amid a year of strong share gains.

Via The Motley Fool

Topics Regulatory Compliance

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors? ↗

June 06, 2026

This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.

Via The Motley Fool

Topics Regulatory Compliance

Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million ↗

June 04, 2026

This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.

Via The Motley Fool

Topics Regulatory Compliance

Twist (TWST) Q2 2026 Earnings Call Transcript ↗

May 04, 2026

Twist (TWST) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

Twist (TWST) Q3 2025 Earnings Transcript ↗

May 04, 2026

Twist (TWST) Q3 2025 Earnings Transcript

Via The Motley Fool

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Via The Motley Fool

Topics Artificial Intelligence

Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation

February 05, 2026

Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging...

Via Finterra

Topics Artificial Intelligence Earnings Economy

TWST Shares Rise 8% — What’s Driving The Rally? ↗

February 02, 2026

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates.

Via Stocktwits

Topics Artificial Intelligence

Twist Bioscience Q1 2026 Earnings Call Transcript ↗

February 02, 2026

Twist Bioscience Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses ↗

November 14, 2025

Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus.

Via Benzinga

Twist Bioscience Corp (NASDAQ:TWST) Stock Falls After Q4 Earnings Miss ↗

November 14, 2025

Twist Bioscience Q4 2025 earnings miss analyst estimates on revenue and EPS, triggering a sharp pre-market stock decline.

Via Chartmill

Topics Earnings

Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings ↗

November 14, 2025

Via Benzinga

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

Earnings Outlook For Twist Bioscience ↗

November 13, 2025

Via Benzinga

This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

November 04, 2025

Via Benzinga

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Warns Wall Street Is Missing AI's Biggest Opportunity In Healthcare, Calling It 'Sleeper' Investment Poised For Massive Returns ↗

October 15, 2025

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential.

Via Benzinga

Topics Artificial Intelligence

Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results ↗

August 05, 2025

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

Via Benzinga

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings ↗

August 04, 2025

Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA breakeven fiscal 2026.

Via Benzinga

Twist Bioscience (TWST) Q3 Profit Surges ↗

August 04, 2025

Via The Motley Fool

Twist Bioscience Corp (NASDAQ:TWST) Reports Mixed Q3 2025 Results with Revenue Miss and EPS Beat ↗

August 04, 2025

Twist Bioscience reported mixed Q3 2025 results, missing revenue estimates at $96.06M but beating EPS at -$0.47. Shares fell 5% pre-market as investors focused on the sales shortfall.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.